Apurva Borcar

Apurva Borcar

Auto-generated profile, based on publicly available information

Apurva Borcar

Department of Anesthesiology, University of Maryland School of Medicine, Baltimore, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2025 in Scientific Data
Verified
Journal Article
Open access
PDF file
ABApurva Borcar
Apurva Borcar
FTFlaubert Tchantchou
Flaubert Tchantchou
ASAmol C. Shetty
Amol C. Shetty
AMAnup Mahurkar
Anup Mahurkar
GFGary Fiskum
Gary Fiskum
Aeromedical evacuation (AE) is an invaluable tool for the transport of critically injured patients to care facilities. There is increasing evidence obtained from animal models and human patients that exposure to AE-relevant hypobaria within a few days of injury can worsen outcomes. The cause of this secondary injury is not well understood but it may be related to changes in gene expression induced by exposure to evacuation-relevant conditions. In order to explore the causes of secondary injury, gene expression induced by AE-relevant flight conditions was analyzed. Adult male rats were exposed to flight cabin-relevant hypobaria (8000 or 4000 ft equivalents) and/or different oxygen concentrations (21% or 100%) for 5 or 10 hr. At the end of the exposures, RNA was isolated from lung, blood, heart, and brain (hippocampus), levels of gene expression were measured via microarray analysis, and canonical pathway analysis identified the primary gene pathways enriched by the exposures. This information should be useful to not only optimize the health status of trauma patients undergoing aeromedical evacuation but also help determine which gene expression pathways could be modulated to optimize the therapeutic efficacy of the body’s endogenous protection and repair mechanisms.

11 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
HHHyehyun Hwang
Hyehyun Hwang
CSChinmoy Sarkar
Chinmoy Sarkar
BPBoris Piskoun
Boris Piskoun
NZNaibo Zhang
Naibo Zhang
ABApurva Borcar
Apurva Borcar
Brian M. PolsterBrian M. Polster
Brian M. Polster
Traumatic Brain Injury (TBI) leads to persistent pro-inflammatory microglial activation implicated in neurodegeneration. Idebenone, a coenzyme Q10 analogue that interacts with both mitochondria and the tyrosine kinase adaptor SHC1, inhibits aspects of microglial activation in vitro . We used the NanoString Neuropathology panel to test the hypothesis that idebenone post-treatment mitigates TBI pathology-associated acute gene expression changes by moderating the pro-inflammatory microglial response to injury. Controlled cortical impact to adult male mice increased the microglial activation signature in peri-lesional cortex at 24 hours post-TBI. Unexpectedly, several microglial signature genes upregulated by TBI were further increased by post-injury idebenone administration. However, idebenone significantly attenuated TBI-mediated perturbations to gene expression associated with behavior, particularly in the gene ontology:biological process (GO:BP) pathways “ephrin receptor signaling” and “dopamine metabolic process.” Gene co-expression analysis correlated levels of microglial complement component 1q ( C1q ) and the neurotrophin receptor gene Ntrk1 to large (>3-fold) TBI-induced decreases in dopamine receptor genes Drd1 and Drd2 that were mitigated by idebenone treatment. Bioinformatics analysis identified SUZ12 as a candidate transcriptional regulator of idebenone-modified gene expression changes. Overall, results suggest that idebenone enhances TBI-induced microglial proliferation within the first 24 hours of TBI and identify Ephrin-A and dopamine signaling as novel idebenone targets.